Twitxy Saved

CSIR-IMTech

Verified account This account is verified. Learn more

@CSIR_IMTECH

CSIR-Institute of Microbial Technology; Integrated research in classical as well as emerging areas of microbiology
facebook.com/imtechchd/
Chandigarh, India imtech.res.in Joined July 2015
322 Following 10K Followers 3.1K Posts

Latest posts 5

CSIR-IMTech Verified account @CSIR_IMTECH
CSIR-IMTECH is pleased to share that Dr. KPS Sengar, Head, KRC & Hindi Cell delivered an Invited Talk at the 6th LISACON 2026: International Conference on Libraries as Experience Centers, jointly organized by LIS Academy and Dr. Manmohan Singh Bengaluru City University from November 12โ€“14, 2026, in Bengaluru.
Speaking under Sub-theme 04 (AI Tools for Scholarly Publishing) on the topic "Strengthening Research Integrity in the Age of Artificial Intelligence: The Evolving Role of Librarians in Scholarly Communication," Dr. Sengar highlighted how rapid advancements in Generative AI are transforming academic publishing and why librarians are emerging as essential guardians of scientific trust.
He also showcased CSIR-IMTech's institutional best practices in strengthening research integrity, including the functioning of its robust Scientific Ethics Committee (SEC), the KRC's primary research data archiving workflow, and systematic pre-submission plagiarism and similarity screening using iThenticate.
The participation provided an opportunity to highlight CSIR-IMTech's proactive initiatives in fostering ethical research practices and reinforcing the role of knowledge resource centres in building a transparent, responsible, and trustworthy scholarly publishing ecosystem in the era of Artificial Intelligence.
@CSIR_IND
#CSIRIMTech #LISACON2026 #ResearchIntegrity #ArtificialIntelligence #GenerativeAI #ScholarlyCommunication #AcademicPublishing #ResearchEthics #LibrariesAsExperienceCenters
CSIR-IMTech Verified account @CSIR_IMTECH
๐—œ๐—ป๐—ฑ๐—ถ๐—ด๐—ฒ๐—ป๐—ผ๐˜‚๐˜€ ๐—ฉ๐—ฎ๐—ฐ๐—ฐ๐—ถ๐—ป๐—ฒ ๐——๐—ฒ๐˜ƒ๐—ฒ๐—น๐—ผ๐—ฝ๐—บ๐—ฒ๐—ป๐˜ ๐—–๐—ฎ๐—ฝ๐—ฎ๐—ฏ๐—ถ๐—น๐—ถ๐˜๐—ถ๐—ฒ๐˜€ ๐—ณ๐—ผ๐—ฟ ๐—™๐˜‚๐˜๐˜‚๐—ฟ๐—ฒ ๐—ฃ๐—ฎ๐—ป๐—ฑ๐—ฒ๐—บ๐—ถ๐—ฐ ๐—ฃ๐—ฟ๐—ฒ๐—ฝ๐—ฎ๐—ฟ๐—ฒ๐—ฑ๐—ป๐—ฒ๐˜€๐˜€ ๐—ฎ๐˜ ๐—–๐—ฆ๐—œ๐—ฅ-๐—œ๐—ป๐˜€๐˜๐—ถ๐˜๐˜‚๐˜๐—ฒ ๐—ผ๐—ณ ๐— ๐—ถ๐—ฐ๐—ฟ๐—ผ๐—ฏ๐—ถ๐—ฎ๐—น ๐—ง๐—ฒ๐—ฐ๐—ต๐—ป๐—ผ๐—น๐—ผ๐—ด๐˜†
The research group led by ๐——๐—ฟ. ๐—ฅ๐—ฎ๐˜ƒ๐—ถ ๐—ฃ.๐—ก. ๐— ๐—ถ๐˜€๐—ต๐—ฟ๐—ฎ (๐—ฆ๐—ฐ๐—ถ๐—ฒ๐—ป๐˜๐—ถ๐˜€๐˜-๐—™) ๐—ฎ๐˜ ๐—–๐—ฆ๐—œ๐—ฅ-๐—œ๐— ๐—ง๐—˜๐—–๐—›, ๐—–๐—ต๐—ฎ๐—ป๐—ฑ๐—ถ๐—ด๐—ฎ๐—ฟ๐—ต, is advancing an indigenous protein subunit vaccine platform to strengthen national pandemic preparedness and response to emerging and re-emerging viral threats.
๐Ÿ”ฌ ๐—ฉ๐—ถ๐—ฟ๐—ฎ๐—น ๐—ฉ๐—ฎ๐—ฐ๐—ฐ๐—ถ๐—ป๐—ฒ ๐—ฃ๐—น๐—ฎ๐˜๐—ณ๐—ผ๐—ฟ๐—บ โ€“ ๐—œ๐— ๐—ง-๐—–๐—ฉ๐—”๐—ซ (๐—ง๐—ฅ๐—Ÿ ๐Ÿฐ)
The platform is based on a recombinant, prefusion-stabilised trimeric SARS-CoV-2 spike protein produced using suspension CHO cells.

๐—ž๐—ฒ๐˜† ๐—ง๐—ฒ๐—ฐ๐—ต๐—ป๐—ผ๐—น๐—ผ๐—ด๐˜† ๐—”๐—ฐ๐—ต๐—ถ๐—ฒ๐˜ƒ๐—ฒ๐—บ๐—ฒ๐—ป๐˜๐˜€:
โ€ข ๐—–๐—›๐—ข-๐—ฏ๐—ฎ๐˜€๐—ฒ๐—ฑ ๐—ฒ๐˜…๐—ฝ๐—ฟ๐—ฒ๐˜€๐˜€๐—ถ๐—ผ๐—ป: Recombinant trimeric spike protein production using mammalian cells.
โ€ข ๐—•๐—ถ๐—ผ๐—ฝ๐—ฟ๐—ผ๐—ฐ๐—ฒ๐˜€๐˜€ ๐—ฑ๐—ฒ๐˜ƒ๐—ฒ๐—น๐—ผ๐—ฝ๐—บ๐—ฒ๐—ป๐˜: Optimised upstream production and bioreactor scale-up, achieving approximately 500 mg/L yield.
โ€ข ๐——๐—ผ๐˜„๐—ป๐˜€๐˜๐—ฟ๐—ฒ๐—ฎ๐—บ ๐—ฝ๐—ฟ๐—ผ๐—ฐ๐—ฒ๐˜€๐˜€๐—ถ๐—ป๐—ด: Integrated purification using tangential flow filtration (TFF) and chromatography.
โ€ข ๐—ฃ๐—ฟ๐—ฒ๐—ฐ๐—น๐—ถ๐—ป๐—ถ๐—ฐ๐—ฎ๐—น ๐˜ƒ๐—ฎ๐—น๐—ถ๐—ฑ๐—ฎ๐˜๐—ถ๐—ผ๐—ป: Strong immune responses and approximately 90% survival in the hamster challenge model.
โ€ข ๐—ง๐—ฟ๐—ฎ๐—ป๐˜€๐—น๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐—ฎ๐—น ๐—ฝ๐—ผ๐˜๐—ฒ๐—ป๐˜๐—ถ๐—ฎ๐—น: An industry-compatible production and purification workflow.

๐ŸŒ ๐—ฃ๐—น๐—ฎ๐˜๐—ณ๐—ผ๐—ฟ๐—บ ๐—”๐—ฑ๐—ฎ๐—ฝ๐˜๐—ฎ๐—ฏ๐—ถ๐—น๐—ถ๐˜๐˜† ๐—ฎ๐—ป๐—ฑ ๐—ฃ๐—ฎ๐—ป๐—ฑ๐—ฒ๐—บ๐—ถ๐—ฐ ๐—ฃ๐—ฟ๐—ฒ๐—ฝ๐—ฎ๐—ฟ๐—ฒ๐—ฑ๐—ป๐—ฒ๐˜€๐˜€
The established CHO-based expression and bioprocess platform offers potential for developing recombinant protein subunit vaccine candidates against other emerging and re-emerging viruses with pandemic potential, including respiratory and zoonotic pathogens. Adaptation of antigen design and production processes could facilitate rapid vaccine proof-of-concept development during future public health emergencies.

๐Ÿ“š ๐—ž๐—ฒ๐˜† ๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต ๐—ฃ๐˜‚๐—ฏ๐—น๐—ถ๐—ฐ๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐˜€
Jitender et al. (2024). ๐˜”๐˜ข๐˜ฎ๐˜ฎ๐˜ข๐˜ญ๐˜ช๐˜ข๐˜ฏ ๐˜ค๐˜ฆ๐˜ญ๐˜ญ ๐˜ฆ๐˜น๐˜ฑ๐˜ณ๐˜ฆ๐˜ด๐˜ด๐˜ฆ๐˜ฅ ๐˜ณ๐˜ฆ๐˜ค๐˜ฐ๐˜ฎ๐˜ฃ๐˜ช๐˜ฏ๐˜ข๐˜ฏ๐˜ต ๐˜ต๐˜ณ๐˜ช๐˜ฎ๐˜ฆ๐˜ณ๐˜ช๐˜ค ๐˜ด๐˜ฑ๐˜ช๐˜ฌ๐˜ฆ ๐˜ฑ๐˜ณ๐˜ฐ๐˜ต๐˜ฆ๐˜ช๐˜ฏ ๐˜ช๐˜ด ๐˜ข ๐˜ฑ๐˜ฐ๐˜ต๐˜ฆ๐˜ฏ๐˜ต ๐˜ท๐˜ข๐˜ค๐˜ค๐˜ช๐˜ฏ๐˜ฆ ๐˜ข๐˜ฏ๐˜ต๐˜ช๐˜จ๐˜ฆ๐˜ฏ ๐˜ข๐˜ฏ๐˜ฅ ๐˜ค๐˜ฐ๐˜ฏ๐˜ง๐˜ฆ๐˜ณ๐˜ด ๐˜ฏ๐˜ฆ๐˜ข๐˜ณ-๐˜ค๐˜ฐ๐˜ฎ๐˜ฑ๐˜ญ๐˜ฆ๐˜ต๐˜ฆ ๐˜ฑ๐˜ณ๐˜ฐ๐˜ต๐˜ฆ๐˜ค๐˜ต๐˜ช๐˜ฐ๐˜ฏ ๐˜ข๐˜จ๐˜ข๐˜ช๐˜ฏ๐˜ด๐˜ต ๐˜š๐˜ˆ๐˜™๐˜š-๐˜Š๐˜ฐ๐˜-2 ๐˜ช๐˜ฏ๐˜ง๐˜ฆ๐˜ค๐˜ต๐˜ช๐˜ฐ๐˜ฏ ๐˜ช๐˜ฏ ๐˜๐˜ข๐˜ฎ๐˜ด๐˜ต๐˜ฆ๐˜ณ. ๐—ฉ๐—ฎ๐—ฐ๐—ฐ๐—ถ๐—ป๐—ฒ, ๐Ÿฐ๐Ÿฎ(๐Ÿฎ๐Ÿฌ), ๐Ÿญ๐Ÿฎ๐Ÿฒ๐Ÿฌ๐Ÿต๐Ÿต.

Singh et al. (2024). ๐˜š๐˜ค๐˜ข๐˜ญ๐˜ข๐˜ฃ๐˜ญ๐˜ฆ ๐˜ฃ๐˜ช๐˜ฐ๐˜ฑ๐˜ณ๐˜ฐ๐˜ค๐˜ฆ๐˜ด๐˜ด ๐˜ง๐˜ฐ๐˜ณ ๐˜ฉ๐˜ช๐˜จ๐˜ฉ-๐˜บ๐˜ช๐˜ฆ๐˜ญ๐˜ฅ ๐˜ฑ๐˜ณ๐˜ฐ๐˜ฅ๐˜ถ๐˜ค๐˜ต๐˜ช๐˜ฐ๐˜ฏ ๐˜ฐ๐˜ง ๐˜š๐˜ˆ๐˜™๐˜š-๐˜Š๐˜ฐ๐˜-2 ๐˜ต๐˜ณ๐˜ช๐˜ฎ๐˜ฆ๐˜ณ๐˜ช๐˜ค ๐˜ด๐˜ฑ๐˜ช๐˜ฌ๐˜ฆ ๐˜ฑ๐˜ณ๐˜ฐ๐˜ต๐˜ฆ๐˜ช๐˜ฏ-๐˜ฃ๐˜ข๐˜ด๐˜ฆ๐˜ฅ ๐˜ช๐˜ฎ๐˜ฎ๐˜ถ๐˜ฏ๐˜ฐ๐˜จ๐˜ฆ๐˜ฏ (๐˜๐˜”๐˜›-๐˜Š๐˜๐˜ˆ๐˜Ÿ) ๐˜ถ๐˜ด๐˜ช๐˜ฏ๐˜จ ๐˜ด๐˜ถ๐˜ด๐˜ฑ๐˜ฆ๐˜ฏ๐˜ด๐˜ช๐˜ฐ๐˜ฏ ๐˜Š๐˜๐˜– ๐˜ค๐˜ฆ๐˜ญ๐˜ญ๐˜ด. ๐—ฃ๐—ฟ๐—ผ๐—ฐ๐—ฒ๐˜€๐˜€ ๐—•๐—ถ๐—ผ๐—ฐ๐—ต๐—ฒ๐—บ๐—ถ๐˜€๐˜๐—ฟ๐˜†, ๐Ÿญ๐Ÿฐ๐Ÿณ, ๐Ÿฏ๐Ÿฏ๐Ÿฎโ€“๐Ÿฏ๐Ÿฐ๐Ÿฒ.

๐Ÿ“‘ ๐—ฃ๐—ฎ๐˜๐—ฒ๐—ป๐˜ ๐—ฃ๐—ผ๐—ฟ๐˜๐—ณ๐—ผ๐—น๐—ถ๐—ผ
โ€ข ๐—ช๐—ข๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฐ๐Ÿฌ๐Ÿฑ๐Ÿฎ๐Ÿต๐Ÿฏ๐Ÿด๐—”๐Ÿญ: Process for recombinant production and purification of SARS-CoV-2 spike protein.
โ€ข ๐—œ๐—ก ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฎ๐Ÿญ๐Ÿญ๐Ÿฌ๐Ÿฏ๐Ÿฌ๐Ÿญ๐Ÿฐ๐Ÿฌ: Recombinant protein for management of SARS-CoV-2 infection.

๐Ÿ“ฉ ๐—–๐—ผ๐—ป๐˜๐—ฎ๐—ฐ๐˜ ๐——๐—ฒ๐˜๐—ฎ๐—ถ๐—น๐˜€
๐——๐—ฟ. ๐—ฅ๐—ฎ๐˜ƒ๐—ถ ๐—ฃ.๐—ก. ๐— ๐—ถ๐˜€๐—ต๐—ฟ๐—ฎ
Scientist-F, CSIR-IMTECH, Chandigarh
โœ‰๏ธ ravipn.mishra@csir.res.in
@DrJitendraSingh @CSIR_IND @ravibhu5
#CSIR #CSIRIMTECH #IndigenousVaccines #VaccineDevelopment #PandemicPreparedness
CSIR-IMTech Verified account @CSIR_IMTECH
๐—”๐—ฝ๐—ฝ๐—น๐—ถ๐—ฐ๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐˜€ ๐—ข๐—ฝ๐—ฒ๐—ป | ๐—–๐—ฆ๐—œ๐—ฅ-๐—œ๐— ๐—ง๐—˜๐—–๐—› ๐—ฆ๐—ถ๐˜…-๐— ๐—ผ๐—ป๐˜๐—ต ๐——๐—ถ๐˜€๐˜€๐—ฒ๐—ฟ๐˜๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ง๐—ฟ๐—ฎ๐—ถ๐—ป๐—ถ๐—ป๐—ด ๐—ฃ๐—ฟ๐—ผ๐—ด๐—ฟ๐—ฎ๐—บ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿณ
CSIR-Institute of Microbial Technology, Chandigarh, invites motivated undergraduate and postgraduate students to undertake their dissertation research under the mentorship of its scientists.

At CSIR-IMTECH, students can explore how proteins function, how microbes produce useful compounds through fermentation, or how computational tools reveal patterns in biological data. The institute brings together expertise in microbiology, protein science and engineering, immunology, fermentation technology and bioinformatics, supported by state-of-the-art laboratories and advanced computing facilities.

Each selected student will work on a focused research project with a faculty mentor, gain hands-on experience in experimental or computational methods, and learn to interpret and present their findings. Beyond the laboratory, IMTECHโ€™s lush green campus in Chandigarh offers a lively academic environment where students can exchange ideas with scientists and fellow research scholars.

๐—ง๐˜„๐—ผ ๐˜๐—ฟ๐—ฎ๐—ถ๐—ป๐—ถ๐—ป๐—ด ๐—ฐ๐˜†๐—ฐ๐—น๐—ฒ๐˜€ | ๐Ÿฏ๐Ÿฌ ๐˜€๐—ฒ๐—ฎ๐˜๐˜€ ๐—ฝ๐—ฒ๐—ฟ ๐—ฐ๐˜†๐—ฐ๐—น๐—ฒ
๐—–๐˜†๐—ฐ๐—น๐—ฒ ๐—œ : Januaryโ€“June 2027 Eligibility cut-off : 30 November 2026
๐—–๐˜†๐—ฐ๐—น๐—ฒ ๐—œ๐—œ : Julyโ€“December 2027 Eligibility cut-off : 30 May 2027
๐Ÿ‘‰ View the detailed advertisement and apply online at imtech.res.in
@DrJitendraSingh @CSIR_IND
#CSIR #CSIRIntegratedSkillInitiative #SkillDevelopment #CSIRIMTECH #DissertationTraining #Biotechnology #StudentResearch
CSIR-IMTech Verified account @CSIR_IMTECH
Antimicrobial resistance (AMR) is an escalating global health challenge, calling for innovative preventive strategies alongside conventional antibiotic development.
๐—–๐—ฎ๐—ป ๐˜ƒ๐—ฎ๐—ฐ๐—ฐ๐—ถ๐—ป๐—ฒ๐˜€ ๐—ฏ๐—ฒ๐—ฐ๐—ผ๐—บ๐—ฒ ๐—ฎ๐—ป ๐—ถ๐—บ๐—ฝ๐—ผ๐—ฟ๐˜๐—ฎ๐—ป๐˜ ๐—ฝ๐—ฎ๐—ฟ๐˜ ๐—ผ๐—ณ ๐˜๐—ต๐—ฒ ๐—ด๐—น๐—ผ๐—ฏ๐—ฎ๐—น ๐—ฟ๐—ฒ๐˜€๐—ฝ๐—ผ๐—ป๐˜€๐—ฒ ๐˜๐—ผ ๐—”๐— ๐—ฅ?
The research group led by ๐——๐—ฟ. @๐—ฅ๐—ฎ๐˜ƒ๐—ถ ๐— ๐—ถ๐˜€๐—ต๐—ฟ๐—ฎ ๐—ฎ๐˜ ๐—–๐—ฆ๐—œ๐—ฅ-๐—œ๐— ๐—ง๐—˜๐—–๐—›, ๐—–๐—ต๐—ฎ๐—ป๐—ฑ๐—ถ๐—ด๐—ฎ๐—ฟ๐—ต, is advancing a novel protein subunit-based bacterial vaccine discovery platform with promising translational potential. The work, published in the peer-reviewed journal Vaccine (2026), highlights an unconventional approach to identifying and validating bacterial vaccine candidates.
๐—ช๐—ต๐—ฎ๐˜ ๐— ๐—ฎ๐—ธ๐—ฒ๐˜€ ๐—ง๐—ต๐—ถ๐˜€ ๐—”๐—ฝ๐—ฝ๐—ฟ๐—ผ๐—ฎ๐—ฐ๐—ต ๐—ก๐—ผ๐˜ƒ๐—ฒ๐—น?
โ€ข AI-assisted reverse vaccinology: Systematic screening of bacterial proteomes to identify unexplored vaccine antigens.
โ€ข Unconventional antigen discovery: Identification of SAUSA300_1684 (IMTS8), a previously uncharacterised hypothetical protein as a promising vaccine candidate.
โ€ข Integrated development approach: Recombinant protein engineering, bioprocess scale-up and preclinical validation.
โ€ข Experimental evidence: 84% survival in a murine model of MDR Staphylococcus aureus infection, compared with 11% in controls.
๐—ฅ๐—ฒ๐—น๐—ฒ๐˜ƒ๐—ฎ๐—ป๐—ฐ๐—ฒ ๐˜๐—ผ ๐—–๐—ผ๐—บ๐—ฏ๐—ฎ๐˜๐—ถ๐—ป๐—ด ๐—”๐— ๐—ฅ
Vaccination can help prevent bacterial infections, potentially reduce antibiotic use and limit opportunities for the emergence and spread of resistance. This integrated discovery platform could be extended to explore vaccine candidates against other high-priority drug-resistant pathogens, including WHO-prioritised ESKAPE bacteria.
๐—ง๐—ต๐—ฒ ๐—ฏ๐—ฟ๐—ผ๐—ฎ๐—ฑ๐—ฒ๐—ฟ ๐˜ƒ๐—ถ๐˜€๐—ถ๐—ผ๐—ป ๐—ถ๐˜€ ๐˜๐—ผ ๐—ฑ๐—ฒ๐˜ƒ๐—ฒ๐—น๐—ผ๐—ฝ ๐—ถ๐—ป๐—ฑ๐—ถ๐—ด๐—ฒ๐—ป๐—ผ๐˜‚๐˜€, ๐˜‚๐—ป๐—ฐ๐—ผ๐—ป๐˜ƒ๐—ฒ๐—ป๐˜๐—ถ๐—ผ๐—ป๐—ฎ๐—น ๐—ฏ๐—ฎ๐—ฐ๐˜๐—ฒ๐—ฟ๐—ถ๐—ฎ๐—น ๐˜ƒ๐—ฎ๐—ฐ๐—ฐ๐—ถ๐—ป๐—ฒ ๐˜๐—ฒ๐—ฐ๐—ต๐—ป๐—ผ๐—น๐—ผ๐—ด๐—ถ๐—ฒ๐˜€ ๐˜๐—ต๐—ฎ๐˜ ๐—ฐ๐—ผ๐—บ๐—ฝ๐—น๐—ฒ๐—บ๐—ฒ๐—ป๐˜ ๐—ฎ๐—ป๐˜๐—ถ๐—ฏ๐—ถ๐—ผ๐˜๐—ถ๐—ฐ๐˜€ ๐—ฎ๐—ป๐—ฑ ๐˜€๐˜๐—ฟ๐—ฒ๐—ป๐—ด๐˜๐—ต๐—ฒ๐—ป ๐˜๐—ต๐—ฒ ๐—ด๐—น๐—ผ๐—ฏ๐—ฎ๐—น ๐—ฟ๐—ฒ๐˜€๐—ฝ๐—ผ๐—ป๐˜€๐—ฒ ๐˜๐—ผ ๐—”๐— ๐—ฅ.
๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต ๐—ฃ๐˜‚๐—ฏ๐—น๐—ถ๐—ฐ๐—ฎ๐˜๐—ถ๐—ผ๐—ป/๐—ฅ๐—ฒ๐—ณ๐—ฒ๐—ฟ๐—ฒ๐—ป๐—ฐ๐—ฒ
Mishra, P.M. et al. (2026). A novel hypothetical protein (SAUSA300_1684) confers excellent protection against multi-drug-resistant Staphylococcus aureus infection in the murine model. Vaccine, 75, 128220. DOI: 10.1016/j.vaccine.2026.128220
@DrJitendraSingh @CSIR_IND
#CSIRIMTECH #AntimicrobialResistance #VaccineDevelopment #ReverseVaccinology #AntigenDiscovery #SubunitVaccines #StaphylococcusAureus